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Abstract
Background: Tissue inhibitor of metalloproteinases-3 (TIMP-3) inhibits matrix metalloproteinases and membrane-bound
sheddases. TIMP-3 is associated with the extracellular matrix and is expressed in highly remodeling tissues. TIMP-3 function
in the hematopoietic system is unknown.
Methodology/Principal Findings: We now report that TIMP-3 is highly expressed in the endosteal region of the bone
marrow (BM), particularly by osteoblasts, endothelial and multipotent mesenchymal stromal cells which are all important
cellular components of hematopoietic stem cell (HSC) niches, whereas its expression is very low in mature leukocytes and
hematopoietic stem and progenitor cells. A possible role of TIMP-3 as an important niche component was further suggested
by its down-regulation during granulocyte colony-stimulating factor-induced mobilization. To further investigate TIMP-3
function, mouse HSC were retrovirally transduced with human TIMP-3 and transplanted into lethally irradiated recipients.
TIMP-3 overexpression resulted in decreased frequency of B and T lymphocytes and increased frequency of myeloid cells in
blood and BM, increased Lineage-negative Sca-1
+KIT
+ cell proliferation in vivo and in vitro and increased colony-forming cell
trafficking to blood and spleen. Finally, over-expression of human TIMP-3 caused a late onset fatal osteosclerosis.
Conclusions/Significance: Our results suggest that TIMP-3 regulates HSC proliferation, differentiation and trafficking in vivo,
as well as bone and bone turn-over, and that TIMP-3 is expressed by stromal cells forming HSC niches within the BM. Thus,
TIMP-3 may be an important HSC niche component regulating both hematopoiesis and bone remodeling.
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Introduction
Hematopoietic stem cells (HSC) have the capacity to self-renew life-
long and to generate all blood lineages, while hematopoieticprogenitor
cells (HPC) possess limited differentiation capacity. Hematopoietic
stem and progenitor cells (HSPC) reside in specific micro-domains of
the bone marrow (BM) called niches. The molecular composition of
niches provides the extrinsic cues that control HSPC fate, such as
quiescence, self-renewal or differentiation. Two types of HSC niches
have been reported: 1) endosteal or osteoblastic niches where HSC are
within 2 cell diameters from osteoblasts lining the endosteum
[1;2;3;4;5], and 2) vascular niches where HSC are in direct contact
with the abluminal side of endothelial cells forming BM sinuses [6;7;8].
The molecular and cellular composition and function of these
HSC niches is under intense investigation. Soluble chemokines
(CXCL12/SDF1), soluble cytokines (angiopoietin-1), transmembrane
cytokines (KIT ligand, Jagged-1) and cell adhesion molecules
(VCAM-1, osteopontin, cadherins, annexin II) are expressed
within these niches and control HSC fate [9;10;11;12].
Proteases produced by BM myeloidcells are important regulators
of some of these HSC niche components, particularly in stress
situations, such as following granulocyte colony-stimulating factor
(G-CSF) stimulation or during recovery from cytotoxic or
radiological insults. The two neutrophil serine-proteases neutrophil
elastase and cathepsin G can cleave and inactivate molecules
important in HSPC retention within the BM, such as VCAM-1, c-
KIT, CXCR4 and CXCL12 [13;14;15;16;17;18]. Once these
interactions are disrupted, HSPC can dislodge from their niches to
circulate in the blood. The matrix metalloproteinases (MMP)-9 and
MT1-MMP (MMP-14) have been reported to play an important
role by cleaving and inactivating CXCL12 and KIT ligand during
mobilization and recovery from cytotoxic insult [15;19;20;21].
Cysteine protease cathepsin K, produced by osteoclasts, has been
reported to cleave CXCL12 and KIT ligand during HSPC
mobilization [22]. Therefore proteases produced within the BM
regulate the molecular composition of niches.
The activity of proteases is controlled by naturally occurring
protease inhibitors. Serine protease inhibitors a1-antitrypsin
(serpina1) and a1-antichymotrypsin (serpina3) are expressed in the
BM to prevent the accidental cleavage of niche components by
neutrophil elastase and cathepsin G [23;24]. However during G-
CSF- and chemotherapy-induced mobilization, these serpins are
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13086down-regulated enabling accumulation of active serine proteases
and subsequent cleavage and inactivation of molecules important in
HSPC retention within the BM [23;25]. Another potentially
important family of protease inhibitors is the tissue inhibitors of
matrix metalloproteinases (TIMP) which comprises 4 members,
TIMP-1 to -4. The archetypal TIMP-1 and TIMP-2 possess an
erythroid potentiating activity in vitro independently of their MMP
inhibitingactivity[26;27;28].HoweverdeletionoftheTIMP-1gene
or over-expression of TIMP-1 or TIMP-2 in vivo did not alter
hematopoiesis in steady-state, nor HSPC mobilization in response
to G-CSF or cytotoxic injury [29].
Among the TIMP family members, TIMP-3 displays unique
molecular features and properties. TIMP-3 has unique domains
that interact with extracellular matrix (ECM) components and,
unlike the other TIMPs, is mainly bound to tissue ECM
[30;31;32]. It is the only TIMP capable of inhibiting membrane
bound MMP, transmembrane MMP and sheddases such as TNF-
a converting enzyme (TACE) also called a disintegrin and
metalloproteinase (ADAM)-17 [33]. Finally, TIMP-3 is a unique
competitive inhibitor of vascular endothelial cell growth factor
(VEGF)-A binding to VEGF receptor 2 (VEGF-R2) [34] and of
angiopoietin-1 to its receptor Tie2 [35].
We now report that TIMP-3 is expressed at the endosteum in
mouse BM by osteoblastic cells, multipotent mesenchymal stromal
cells (MSC) and endothelial cells and is the only TIMP down-
regulated during G-CSF-induced mobilization. Finally, over-
expression of huTIMP-3 in hematopoietic cells results in increased
HSPC proliferation and trafficking, and myelopoiesis in vivo
leading to progressive and ultimately fatal osteosclerosis.
Results
Decrease in TIMP-3 Expression during G-CSF Induced
Mobilization of HSPC
Similarly to neutrophil serine-proteases, MMP-9 protein levels
increase in the BM during G-CSF-induced mobilization
[14;18;19]. As serpin expression decreases during mobilization
[23;25], we investigated expression of MMP inhibitors in the
mobilized BM. Reverse zymography of pooled BM fluids from G-
CSF-mobilized mice revealed that the concentration of a 27 kDa
TIMP protein corresponding to the molecular weight of TIMP-3
and migrating as previously reported between recombinant
human TIMP-1 (30 kDa) and TIMP-2 (22 kDa) [36;37;38],
decreased during G-CSF administration between days 0 and 6 and
rebounded at day 8, 2 days after cessation of G-CSF administra-
tion (Figure 1A–B). 30 kDa TIMP-1 was slightly increased.
To determine whether TIMP-1 and -3 were transcribed in the
BM, we quantified TIMP-1 and TIMP-3 mRNA from the central
BM and the endosteal region by real-time RT-qPCR. TIMP-3
mRNA was expressed more abundantly at the endosteum than the
central BM and G-CSF administration decreased TIMP-3 expression
at both endosteum and central BM (Figure 1C–D).TIMP-1mRNA
expression was also more abundant at the endosteum than in the
central BM (Figure 1E–F). However, unlike TIMP-3, TIMP-1
mRNA and protein were increased in the central BM and BM fluids
during G-CSF administration (Figures 1A and 1F). Taken
together, these data show that TIMP-3 expression in the BM is
decreased at both mRNA and protein levels during G-CSF
administration whereas TIMP-1 expression is slightly increased.
High Expression of TIMP-3 in Stromal Cells at the
Endosteum
We next explored TIMP-3 expression pattern by RT-qPCR in
various cell populations from the BM. TIMP-3 was expressed at
10-fold higher levels in the endosteal region compared to central
BM (Figure 2A). To further elucidate which endosteal cell
populations most abundantly expressed TIMP-3, we sorted
CD45
2Lin
2CD31
bright endothelial cells, CD45
2Lin
2CD31
2
Sca1
bright MSC with adipogenic, chondrogenic and osteogenic
potential [39;40;41], and CD45
2Lin
2CD31
2Sca1
2CD51
+ oste-
oblast lineage cells from endosteal cells extracted by collagenase
treatment of bone fragments washed of the central BM [39;40;41].
Endothelial cells, MSC and osteoblastic cells all expressed high
levels of TIMP-3 mRNA (Figure 2B).
In contrast, TIMP-3 expression in hematopoietic cells sorted
from the central BM was very low to undetectable. Specifically
Ter119
+CD45
+ erythroid progenitors, CD41
+ megakaryocytes
and CD41
+KIT
+ megakaryocyte progenitors expressed TIMP-3 at
10-fold lower levels compared to non-hematopoietic stromal cells.
In HSPC such as Lin
2Sca1
+KIT
+ (LSK) HSPC, common
myeloid progenitors (CMP), granulocyte-monocyte progenitors
(GMP) and megakaryocyte-erythrocyte progenitors (MEP),
TIMP-3 expression was less than 1/100
th of stromal cells.
TIMP-3 mRNA was undetectable (Ct.45) in the lineage positive
leukocytes such as B220
+ B cells, CD3
+ T cells, Gr-1
bright
granulocytes, and CD11b
+Gr1
2 myeloid cells (Figure 2B).
Immunohistofluorescence on fixed bone sections confirmed
TIMP-3 expression in bone lining osteoblasts, endothelial cells as
well as in megakaryocytes (Figure 2C).
Expression of TIMP-3 in megakaryocytes led us to examine
TIMP-3 protein in blood plasma and platelets. Reverse zymo-
graphy revealed that mouse blood plasma, serum and platelet
lysates contained functional TIMP capable of inhibiting MMP-2
degradation of gelatin and migrating at same apparent molecular
weight as commercial purified rmuTIMP-3 containing both
27 kDa glycosylated TIMP-3 and 24 kDa unglycosylated TIMP-
3 [36] (Figure 2D). Therefore, while TIMP-3 in the BM could be
essentially produced by BM stromal cells, particularly MSC,
osteoblasts and endothelial cells, blood TIMP-3 is more likely to be
released from mature platelets.
Generation of Retroviral Vector to Overexpress huTIMP-3
in Murine Hematopoietic Cells in Vivo
To study the role of TIMP-3 in hematopoiesis, full length
huTIMP-3 cDNA was cloned into retroviral vector MND-X-
IRES-eGFP (MXIE) a vector less susceptible to gene silencing
compared to the earlier generation MSCV vector [42]. The intra-
ribosomal entry site (IRES) enables translation of both huTIMP-3
and GFP from the same transcript. Thus, cells that expressed GFP
also expressed huTIMP-3 (Figure 3A).
We first assessed the effectiveness of the MXIE vector by
retrovirally transducing the mouse myeloid cell line FDC-P1.
Following sorting of GFP
+ transduced FDC-P1 cells, we could
demonstrate by PCR with primers specific for huTIMP-3 genomic
integration and RNA expression of huTIMP-3 in cells transduced
with MIXIE-huTIMP-3 but not in cells transduced with empty
MIXIE (Figure 3B-C). Reverse zymography showed that
functional huTIMP-3 was secreted by FDC-P1 cells transduced
with MXIE-huTIMP-3 but not by cells transduced with MXIE
control vector (Figure 3D).
huTIMP-3 Overexpression Increases Myelopoiesis and
Decreases Lymphopoiesis in Vivo
We then used this vector to retrovirally transduce BM cells from
5-FU-primed B6.SJL-PtprcaPep3b/BoyJ mice and then trans-
planted these transduced cells into lethally irradiated C57BL/6
congenic recipients. Eight weeks after transplantation, 10–35%
TIMP-3 Regulates Hematopoiesis
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+ (average 22%) in mice reconstituted
with MXIE-transduced HSC, and 6-24% blood leukocytes were
GFP
+ (average 16%) in mice reconstituted with MXIE-huTIMP-
3-transduced HSC. Fourteen weeks post-transplant, using hu-
TIMP-3 specific primers we confirmed by RT-qPCR that mice
transplanted with MXIE-huTIMP-3-transduced BM cells ex-
pressed huTIMP-3 in central BM and endosteal regions whereas
it was undetectable in mice transduced with MXIE vector (Figure
S1A). Forced huTIMP-3 expression did not alter endogenous
muTIMP-3 expression (Figure S1B).
Fourteen weeks post-transplant, mice reconstituted with hu-
TIMP-3-transduced HSPC did not show any significant difference
Figure 1. Decreased TIMP-3 expression level during G-CSF induced mobilization. (A) Detection by reverse zymography of TIMP-1 and
TIMP-3 proteins from mouse BM fluids following mobilization with G-CSF. G-CSF was administered twice daily from day 0 to day 6 and the left to rest
for 2 days (day 8 group). Each sample is a pool of BM fluids from 4 mice per time point. Controls were made with recombinant human TIMP-1 (0.1 and
0.3 ng) and TIMP-2 (1 ng). (B) Quantification of TIMP-3 and TIMP-1 protein concentrations during G-CSF induced mobilization from panel A. (C–D)
TIMP-3 mRNA expression by RT-qPCR in cells from the endosteal region (C) and central BM (D). Data are normalized to B2M expression and are
average 6 SD of at least 4 mice per time-point. * indicates a p value of 0.03 compared to control mice. (E–F) TIMP-1 mRNA expression in endosteal (E)
and central BM (F).
doi:10.1371/journal.pone.0013086.g001
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femur, spleen weight or splenocyte number compared to MXIE
controls (Figure S1C-G).
Lineage analysis by flow cytometry showed that in mice over-
expressing huTIMP-3, CD11b
+ myeloid cells were significantly
over-represented amongst transduced GFP
+ leukocytes in the BM,
blood and spleen (Figure 4A). Conversely, the proportion of
CD11b
2B220
+ B cells amongst transduced GFP
+ huTIMP-3
over-expressing cells was significantly reduced in the blood and
BM when compared to MXIE controls (Figure 4B). The
proportion of CD3
+ T cells among transduced GFP
+ huTIMP-3
over-expressing cells was also significantly reduced in the blood
and BM compared to MXIE controls (Figure 4C). Therefore,
huTIMP-3 over-expression in hematopoietic cells favored myelo-
poiesis at the detriment of lymphopoiesis.
Unexpectedly, the frequencies of total (GFP
+ and GFP
2)
myeloid, B and T cells were similar between the empty MXIE
and MXIE-huTIMP-3 groups (Figure 4D). As TIMP-3 is not
Figure 2. TIMP-3 expression pattern in the BM. (A) Comparison of TIMP-3 mRNA expression between endosteal and central BM cells by RT-
qPCR. Data are mean 6 SD of at least 7 mice per group normalized to B2M. (B) TIMP-3 mRNA in cells sorted from collagenase-treated compact bones
or central bones. Phenotypes used are described in Supplementary Materials and Methods. Data are mean 6 SD of at least 3 mice per group
normalized to B2M. (C) TIMP-3 immunohistofluorescence by confocal laser scanning microscopy on bone sections x40 magnification. Two left panels
are with rabbit anti-TIMP-3 antibody, two right panel with control non-immune rabbit IgG. Green color shows anti-TIMP-3 fluorescence whereas the
pink color shows nuclei stained by DAPI. Osteoblasts (OB), endothelial cells (endo) and megakayocytes (MK) are indicated. (D) Reverse zymography of
mouse blood plasma, sera and platelet lysates. Glycosylated and unglycosylated TIMP-3, and TIMP-2 are indicated. M lane contains molecular weight
markers, + lane contains 20 ng of rmuTIMP-3.
doi:10.1371/journal.pone.0013086.g002
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of huTIMP-3 into the ECM surrounding huTIMP-3 secreting
cells may have prevented huTIMP-3 diffusion to neighboring
GFP
2 cells which did not express huTIMP-3. To test the level of
TIMP-3 secretion, reverse zymography was performed on 10 mg
of total protein from BM fluid of retrovirally transduced mice.
There was a significant but moderate 20% increase in the
concentration of total free soluble functional TIMP-3 (of both
mouse and human origins) compared to BM fluids from mice
transduced with empty-MXIE (Figure 4E–F). Therefore, this
20% increase in total soluble TIMP-3 concentration in BM fluids,
due to the retrovirally induced expression of huTIMP-3 over
endogenous expression of muTIMP-3, may not have been
sufficient to affect non-transduced hematopoietic cells.
huTIMP-3 Overexpression Increases Colony Forming Cells
(CFC) Trafficking
As a1-antitrypsin related serpins affect HSPC trafficking
[23;25], we tested if huTIMP-3 over-expression altered HSPC
distribution between BM, blood and spleen. Colony assays
showed that huTIMP-3 over-expression had no effect on the
number of CFC per femur (Figure 5C). However, spleen from
MXIE-huTIMP-3 mice contained 2.4-fold more CFC than
spleens from mice transduced with empty MXIE (Figure 5A).
Similarly CFC were detected in the blood of 4 out of 9 MXIE-
TIMP3 mice while CFC were undetectable in the blood of 9 out
of 9 control MIXE mice (Figure 5B,p=0 . 0 4F i s h e r ’ sE x a c tt e s t ) .
This suggests that huTIMP-3 over-expression in hematopoietic
cells slightly increases HSPC trafficking leading to accumulation
in the spleen.
huTIMP-3 Increases HSPC Proliferation in Vivo and in Vitro
In order to estimate HSPC turnover in mice over-expressing
huTIMP-3, transplanted mice were given 5-bromo-2-deoxyur-
idine (BrdU) for three days before sacrifice. GFP
+ LSK cells
expressing huTIMP-3 had significantly increased BrdU incorpo-
ration in vivo (Figure 6A), demonstrating increased HSPC
proliferation in vivo. This was confirmed when transduced GFP
+
LSK cells were sorted from the BM of transplanted mice and
cultured in serum-free medium in the presence of recombinant
cytokines (ratKIT ligand, huIL-6, huIL-11 and huFlt3 ligand).
After 12 days of cultures, huTIMP-3 over-expressing LSK
expanded 2.7-fold more than LSK transduced with the control
vector (Figure 6B).
To test whether this increased HSPC proliferation in mice over-
expressing huTIMP-3 was a direct effect of TIMP-3, LSK cells
were sorted from naı ¨ve C57BL/6 mice and cultured in vitro in
absence or presence of 200 ng/mL rhuTIMP-3. After 7 days of
culture, rhuTIMP-3 significantly increased LSK proliferation by
1.4 fold (Figure 6C). Thus, huTIMP-3 increases the proliferation
of LSK cells both in vivo and in vitro.
Fatal Osteosclerosis in Mice Overexpressing huTIMP-3
To determine the long-term effects of over-expressing huTIMP-
3 in hematopoietic cells, a cohort of mice were maintained for a
year. Unexpectedly, a significant proportion of mice transplanted
with MXIE-huTIMP-3 HSPC died between 36 and 39 weeks after
transplantation (Figure 7A). In MXIE-huTIMP-3 mice that died
first, it was impossible to flush the BM as the BM cavity was filled
with solid bone. Examination of the tibias and femurs from mice
overexpressing huTIMP-3 that survived, revealed that the BM
Figure 3. Retroviral vector to over-express huTIMP-3 in murine hematopoietic cells. (A) Representation of the MXIE retroviral vector
containing huTIMP-3, an IRES, and GFP thus allowing for the co-expression of huTIMP-3 and GFP. (B) PCR and (C) RT-PCR of genomic DNA and RNA
respectively from retrovirally transduced mouse hematopoietic cell line. M is markers, Mock are non-transduced cells, MXIE are cells transduced with
empty-MXIE vector and MXIE-huTIMP-3 are cells transduced with the MXIE-huTIMP3 vector. + lane is the original plasmid containing huTIMP-3 cDNA
as positive control. (D) Reverse zymography of culture supernatants from different clones of FDCP1 cells transduced with empty MXIE or MXIE-
huTIMP-3 vectors. M is molecular weight markers, and + is 25 ng rhuTIMP-3.
doi:10.1371/journal.pone.0013086.g003
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decreased BM content (Figure 7B–C) with a large amount of
trabecular bone in the metaphysis and epiphysis. In the regions
where trabecular bone areas were increased, cortical bone was also
highly porous, suggesting destruction or lack of development of the
normal cortical structure. The excess bone was woven in nature
and the endosteal surfaces were largely inactive; without any
morphologically identifiable osteoblasts or osteoclasts on the bone
surfaces (Figure 7C). No cartilage remnants were detected within
the trabecular bone, indicating that this excess bone did not arise
because of a lack of resorption of newly formed trabecular bone.
Rather, it seems that an excessive amount of bone formation
occurred at some time prior to sample collection but was not
continuing at the time of death as osteoblasts were absent. Clearly
the normal signaling pathways which would activate remodeling of
the bone did not respond by increasing bone turnover to remove
the excess bone, leading to a premature exhaustion of the
osteoblastic lineage.
Discussion
In embryos and early post-natal mice, TIMP-3 is expressed at
sites of extensive tissue remodeling such as developing bony
structures and somites, lung, skin, hair follicles, ear, external
Figure 4. Flow cytometry analysis of leukocytes in mice over-expressing huTIMP-3 in hematopoietic cells. Frequency of CD11b
+
myeloid cells (A), B220
+ B cells (B) and CD3
+ T cells (C) among GFP
+ transduced cells in the BM, blood and spleen of mice reconstituted with HSC
transduced with empty MXIE vector (white columns) or MXIE-huTIMP3 vector (black column). Data are mean 6 SD of 9 mice per group. (D)
Proportion of CD11b
+ myeloid cells, B220
+ B cells and CD3
+ T cells in the BM, spleen and blood of the same mice when GFP expression was not taken
into consideration. Data are mean 6 SD of 9 mice per group. (E) Reverse zymography of BM fluids from mice transplanted with HSC transduced with
empty MXIE vector or MXIE-huTIMP3 (n=5 per group). M is molecular weight marker, + is 25 ng of rhuTIMP-3. (F) Quantification of the integrated
intensity of TIMP-3 bands from panel E.
doi:10.1371/journal.pone.0013086.g004
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[43]. In adult mice, TIMP-3 mRNA and protein were detected in
a the kidney cortex, liver, spleen, muscle, heart, brain, ovarian
follicles, testis and hair follicles [43]. Relevant to our study, TIMP-
3 was also found to be expressed in adult bones but its expression
in the hematopoietic system has not been investigated [43].
We report that TIMP-3 is highly expressed in the endosteal
region compared to central BM. Endothelial cells, MSC and
osteoblastic cells, which are all important cellular components of
HSC niches [6;7;44;45;46;47], express high levels of TIMP-3.
Megakaryocytes, their progenitors, and erythroid progenitors also
expressed TIMP-3 mRNA at much lower levels. At the protein
level, megakaryocytes and platelets were positive for TIMP-3. This
is consistent with previous reports showing that fibroblasts,
erythroid and megakayrocyte progenitors derived from human
long-term marrow cultures express TIMP-3 [48] and that
huTIMP-1, -2 and -3 are present in platelets [49]. Myeloid cells,
lymphoid cells, Lin
2 myeloid progenitors and LSK HSPC tested
showed no detectable TIMP-3 expression. As non-hematopoietic
stromal cells at the endosteum express high levels of this protein,
TIMP-3 could be an important component of HSPC niches and
regulate hematopoiesis in vivo. This is supported by 1) our
observation that TIMP-3 expression is reduced during G-CSF-
induced mobilization and 2) that TIMP-3 is expressed in hair
follicle bulges that form specific niches for epidermal stem cells and
its expression is up-regulated when quiescent epidermal stem cells
shift towards a proliferative state [50]. Furthermore, we show
herein that over-expression of huTIMP-3 in hematopoietic cells in
vivo 1) increases LSK cell proliferation, 2) favors myelopoiesis at
the detriment of lymphopoiesis 3) increases trafficking of CFC to
the spleen and 4) results in late onset fatal osteosclerosis whereby
most of the BM cavity was filled with mineralized bone,
demonstrating that TIMP-3 is a key regulator of both hemato-
poiesis and bone turn-over.
Our data showing increased BrdU incorporation in LSK cells
following in vivo or in vitro exposure to TIMP-3 are consistent
with a recent report showing that in vivo overexpression of TIMP-
3 in mice for a period of 8 days by hydrodynamic transfection
caused increased HSC proliferation with increased production of
multipotent progenitors independently of TIMP-3 protease
inhibitory domain [35]. As a result, hydrodynamic transfection
of TIMP-3 in 5-FU treated mice accelerated recovery whereas
TIMP-3 deficient mice had blunted recovery from 5-FU [35].
However these authors did not investigate longer term effects of
TIMP-3 overexpression on myelopoiesis, HSPC trafficking and
bone formation.
TIMP-1 and TIMP-2 are known to have erythroid-potentiating
activity [26] and promote proliferation of a variety of human and
mouse hematopoietic and non-hematopoietic cell lines in vitro
[27;28]. Therefore, growth promoting activity of TIMP-3 in vitro
Figure 5. Increased CFC trafficking in mice over-expressing huTIMP-3. Colony-forming cell number in spleen (A), blood (B) and femoral BM
(C) from mice transplanted with HSC transduced with empty MXIE vector (white columns) or MXIE-huTIMP3 vector (black columns). Data are mean 6
SD of 9 mice per group.
doi:10.1371/journal.pone.0013086.g005
Figure 6. huTIMP-3 increases LSK cell proliferation in vivo and in vitro. (A) Proportion of transduced LSK cells that incorporated BrdU in vivo
after 3 day BrdU administration. Data are mean 6 SD of 5 mice per group. (B) In vitro proliferation of transduced LSK cells after 12 days of culture. LSK
cells were seeded at 4,000/mL. Data are average 6 SD of triplicates. (C) Day 7 effect of the addition of 200 ng/mL purified rhuTIMP-3 to liquid culture
of LSK cells from non-manipulated mice. Data are mean 6 SEM of 2 mice in quadruplicates.
doi:10.1371/journal.pone.0013086.g006
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TIMP-3, over-expression of TIMP-1 or TIMP-2 in hematopoietic
cells using a MSCV retroviral vector similar to MXIE did not
affect murine hematopoiesis in vivo [29]. Although huTIMP-3
over-expression using the MXIE retroviral vector was not
sufficiently high to cause global effects on BM hematopoiesis,
our data show that LSK HSPC overexpressing huTIMP-3
proliferate faster and traffic more with their differentiation skewed
towards myelopoiesis at the detriment of lymphopoiesis in vivo.
Because TIMP-3 has multiple functions in addition to MMP
inhibition, the unique effects of TIMP-3 over-expression on
hematopoiesis in vivo compared to the lack of effect of TIMP-1 or
TIMP-2 over-expression is likely to lie beyond TIMP-3 MMP
inhibitory activity, in unique functions that TIMP-1 and TIMP-2
do not possess.
Due to unique basic domains both at the C- and N-terminus of
TIMP-3, the majority of the protein is bound to the ECM,
whereas the other members of the TIMP family are found in a
soluble form [30;31;32]. In addition to inhibiting soluble MMP,
TIMP-3 is also able to inhibit membrane bound and transmem-
brane MMP [51;52]. The long-term over-expression of huTIMP-3
in murine hematopoietic cells resulted in late onset and dramatic
osteosclerosis, eventually resulting in death. The volume of
trabecular bone depends on the coordinated actions of osteoblasts
(bone forming cells) and osteoclasts (bone destroying cells). The
increased bone volume must be caused either by inhibited
osteoclastic bone resorption or increased bone formation, but
the exact cause is unclear. The lack of cartilage remnants and the
woven bone present in the aged TIMP-3 over-expressing samples
suggests that there has been an excess of bone formation. This was
Figure 7. Long-term over-expression of huTIMP-3 in hematopoietic cells leads to fatal osteosclerosis. (A) Survival curve of mice
transplanted with HSC transduced with empty MXIE vector or MXIE-huTIMP3 vector (n=10 in each group). (B) von Kossa staining and toluidine blue
staining (C) of tibial sections from mice transplanted with HSC transduced with empty MXIE vector or MXIE-huTIMP3 vector. In panel B, black staining
shows calcified bone. In panel C, cuboidal osteoblasts covering the osteoid are indicated by empty arrow heads. Note that osteoblasts and osteoid
are absent in mice transduced with MXIE-huTIMP3.
doi:10.1371/journal.pone.0013086.g007
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MMP-9 and MT1-MMP, have focused on their essential roles as
bone-degrading proteases required for osteoclast function
[53;54;55]. Furthermore, mice lacking MMP-13 are reported to
have increased bone volume due to decreased osteoclast formation
and function, but also demonstrate enhanced osteoblast function
[56;57]. TIMP-1 and TIMP-2 inhibit bone resorption in vitro; and
in young mice, TIMP-1 over-expression reduces bone resorption
resulting in increased bone mass [58;59]. Synthetic inhibitors of
MMPs and TIMP-2 can also inhibit osteoclast migration to bone
resorption site, thus decreasing bone remodeling [60].
The lack of osteoblast in mice over-expressing huTIMP-3 in
hematopoietic cells may have occurred due to over-stimulation
and proliferation of osteoblast progenitors following transplant,
leading to a massive burst of bone formation followed by the
exhaustion of the osteoblastic lineage, resulting in their complete
loss from endosteal surfaces. Therefore, although osteoblasts and
their MSC ancestors express TIMP-3, excessive TIMP-3 may
cause excessive proliferation and differentiation towards the
osteoblastic lineage and exhaustion of the mesenchymal/osteo-
blastic cell reserve in the BM. Because osteoblast lineage cells and
MSC are an integral part of the HSC niche, their disappearance
may have compromised HSC niches within the BM, leading to
decreased hematopoiesis and ultimately death. The progressive
and eventually fatal osteosclerosis may be responsible for the slight
but significant increase in splenic hematopoiesis 14 weeks
following transplantation of HSPC transduced with huTIMP-3.
This late onset osteoclerosis could be due to the relatively small
enhancement of huTIMP-3 expression over endogenous mu-
TIMP-3 expression.
Another unique property of TIMP-3 is its ability to inhibit
angiogenesis by specifically blocking the binding of VEGF-A to its
receptor VEGF-R2. This inhibition prevents the phosphorylation
of VEGF-R2 and down-stream signaling events that would
normally promote vascular formation [34]. TIMP-3 can reduce
circulating endothelial progenitors and decrease neovasculariza-
tion in tumors both in vitro and in vivo [61;62;63]. VEGF-A has also
been found to be a chemo-attractant for osteoclasts, essential for
osteoclast migration and invasion and promote osteoclast bone
resorption [54;64]. Therefore, the ability of huTIMP-3 to affect
VEGF-A activity and binding may also play a role in the
osteosclerosis seen in mice transplanted with huTIMP-3 trans-
duced BM cells.
Interestingly, Nakajima et al have recently reported that similar
to VEGFR2, TIMP-3 can directly bind to the receptor tyrosine
kinase Tie2 expressed by HSC, inhibiting its phosphorylation in
response to its ligand angiopoietin-1 resulting in HSC release from
quiescence [35]. As angiopoietin-1 is expressed by osteoblast-
lineage cells, MSC and to a lower extent by endothelial cells at the
endosteum [41], it is also possible that part of the effect we
observed is mediated by inhibition of Tie2-mediated signaling.
Finally, TIMP-3 has the unique property amongst TIMP family
to inhibit membrane bound sheddases of the ADAM family,
particularly TACE (or ADAM-17), which converts membrane-
bound pro-TNFa into active soluble TNFa [33]. By inhibiting
TACE activity and inhibiting TNFa maturation, TIMP-3 is an
important negative regulator of TNFa. Deletion of the TIMP-3
gene in mice leads to chronic hepatic inflammation, systemic
inflammation after lipospolysaccharide administration and death
due to uncontrolled TNFa activation [33;65;66]. Importantly Cre-
mediated conditional inactivation of TACE gene in osteochon-
droprogenitors via the Sox9 promoter leads to decreased B cells
and T cells, increased granulocytes, extramedullary hematopoiesis
in the spleen and liver as well as increased LSK cell number in the
BM [67]. The phenotype in this mouse model is very similar to
what we observed by over-expressing huTIMP-3 in haematopoi-
etic cells in vivo. Additionally, TACE processes a number of trans-
membrane proteins controlling HSPC functions such as IL-6
receptor [68], Notch-1 [69], Notch ligand Delta 1 [70], CSF-1
receptor [71], VCAM-1 [72], c-KIT [73] and Flt3-L [74].
Therefore, the effect of huTIMP-3 over-expression may not be
limited to the alteration of TNF-a activation in the BM but also
include decreased processing of these important hematopoietic
cytokines expressed in BM niches. Therefore, it is tempting to
speculate that part of the effect of huTIMP-3 overexpression on
HSPC proliferation, myelopoiesis, lymphopoiesis and trafficking to
the spleen could be due to TIMP-3-mediated inhibition of TACE
in osteochondroprogenitors forming HSC niches.
In conclusion, our results suggest that TIMP-3 is an important
component of HSC niches and regulates both HSC and bone
turn-over. This is supported by our finding that 1) most TIMP-3 is
expressed at the endosteum by stromal cells known to form HSC
niches, 2) TIMP-3 mRNA and protein expression decreases under
hematopoietic system stress such as G-CSF induced mobilization,
3) over-expression of huTIMP-3 increases HSPC proliferation in
the BM, 4) favors myelopoiesis at the detriment of lymphopoiesis
and 5) increases bone formation while decreasing bone resorption
in vivo.
Materials and Methods
Mice
All procedures were approved by the Animal Ethics Experi-
mentation Committee of the University of Queensland, Australia.
Mice used for TIMP-3 localization studies were 12-14 wk male
C57BL/6. For mobilization experiments, 8 week-old male
C57BL/6 mice were subcutaneously injected twice daily with a
total of 250 mg/kg/day of recombinant human G-CSF (Neupo-
gen) diluted in saline.
In the transplant studies, 9 week old male B6.SJL-PtprcaPep3b/
BoyJ BM (CD45.1
+) were retrovirally transduced to over-express
huTIMP-3 and transplanted into 11 wk female C57Bl/6
(CD45.2
+). For late effect of TIMP-3 over-expression, HSC
donors and recipients were 8.5 week 129Sv. All mice were
purchased from the Animal Resource Centre (Western Australia,
Australia).
Tissue Harvesting
On the day of sacrifice, mice were weighed and anesthetized
with isofluorane for cardiac puncture prior to sacrifice by cervical
dislocation. Blood was collected into 20 U of heparin before red
cell lysis in 0.15 M NH4Cl, 10 mM NaHCO3, 1 mM EDTA
pH=7.4 buffer. Hips, single femur and spine were surgically
removed, cleaned and placed into a tube containing PBS
supplemented with 2% newborn calf serum (NCS) for crushing.
The remaining femur was flushed with 1 mL PBS and the emptied
bone was kept for further RNA extraction. BM fluid was collected
after pelleting the femur flush at 370 g and stored at -70uC.
Spleens were weighed before being dissociated in PBS with 2%
NCS. Tibias were fixed in ice cold PBS containing 4%
paraformaldehyde and rotated overnight at 4uC. A single tibia
was allowed to decalcify in 10% EDTA for 2-3 weeks before
paraffin embedding.
Quantitative Real-Time RT-PCR (RT-qPCR)
2–4610
6 BM cells from the flushed femur were extracted with
1 mL Trizol (Invitrogen, USA). Endosteal RNA was collected by
flushing the empty femur with 1 mL Trizol to extract cells
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hexamers (Roche, Switzerland) and SuperScriptIII (Invitrogen,
USA). Primers were designed to cross intron-exon boundaries that
do not amplify genomic DNA. Taqman probe ‘‘mu/huTIMP3
probe 639b’’ was used in conjunction with mouse (mu) specifc or
human (hu) specific TIMP-3 primers (Table 1). The probe was
labeled with 59 FAM and 39 BHQ1. RT-qPCR reactions were
performed following manufacturer’s instructions using 8 mLo fa
1/20 dilution of cDNA (ABI systems/Invitrogen, USA). Samples
were standardized to the house-keeping gene b2-microglobulin
(B2M) and amplified with specific primers (Table 1).
Colony Assays
Leukocytes from BM, blood and spleens were counted on a
Sysmex KX-21 automated cell counter. Colony assays, done in
duplicates, were performed with 2610
5 cells plated in 35 mm Petri
dishes containing 1 mL of Iscove’s Modified Dulbecco’s Medium
(IMDM) with 1.62% methylcellulose (Fluka, USA), 30% fetal calf
serum and saturating doses of recombinant muIL-3, muIL-6 and
muSCF conditioned media from stably transfected X63 and BHK
cell lines. Colonies were counted after 12 days of culture at 37uC
with 5% CO2.
Flow Cytometry Staining and Cell Sorting
To sort CMP, GMP and MEP from the BM, the following
stain was performed in PBS with 2% NCS: Biotinylated anti-
lineage (Lin) antibody cocktail (CD3, CD5, B220, Gr1, F4/80,
Ter119) and biotinylated anti-IL7Ra with streptavidin (SAV)-
Pacific Blue, CD34-fluorescein isothiocyanate (FITC), CD16/
32-phycoerythrin (PE), Sca-1-phycoerythrin-cyanine 7 (PECY7)
and Kit-allophycocyanin (APC). The populations were defined
as follow: Lin
2IL7Ra
2Kit
+Sca-1
2CD34
+CD16/32
2 (CMP),
Lin
2IL7Ra
2Kit
+Sca-1
2CD34
+CD16/32
+ (GMP) and Lin
2IL7-
Ra
2Kit
+Sca-1
2CD34
2CD16/32
2 (MEP) [75].
All other stains were performed in CD16/CD32 hybridoma
2.4G2 supernatant (Fc block) to block IgG Fc receptors. BM cells
stained with CD11b-PE and Gr-1-FITC were sorted for
monocyte/myeloid cells (CD11b
+Gr-1
2) and granulocytes
(CD11b
+Gr-1
bright). Megakaryocytes (CD45
+CD41
+), pro-eryth-
roblasts (CD45
+Ter119
+) and their KIT
+ progenitors were stained
and sorted using Ter119-FITC, Kit-PE, CD45-allophycocyanin-
cyanine 7 (APCCY7) and CD41-biotin with SAV-Pacific Blue.
BM cells stain with B220-FITC, CD11b-PECY7 and CD3-
Peridinin chlorophyll protein 5.5 (PerCPCY5.5) were sorted for
B cells (CD11b
2B220
+) and T cells (CD11b
2CD3
+). Populations
collected were mixed in Trizol for qRT-PCR analysis.
To sort endosteal cells associated with the bone, cleaned hips,
femurs, tibias and spine were crushed and BM cells were discarded.
Following treatment with 3 mg/mL collagenase type I from C.
histolyticum (Worthington, USA) for 40 min at 37uC, bone cells
were washed through a 40 mm filter, pelleted at 370 g and
resuspended in Fc block. Biotinylated lineage antibodies (CD3,
CD5, Gr-1, B220, CD11b and Ter119) and SAV-conjugated
magnetic activated cell sorting (MACS) beads were used to
magnetically deplete mature hematopoietic cells. Lineage negative
cells were then stained with SAV-FITC, CD51-PE, Sca-1-PECY7,
CD31-APC and CD45-APCCY7 and sorted. The following
populations were collected: endothelial cells (CD45
2Lin
2
CD31
bright), MSC (CD45
2Lin
2CD31
2CD51
+Sca-1
bright)a n d
osteoblast/osteoprogenitors (CD45
2Lin
2CD31
2CD51
+ Sca-1
2)
[76;77;78]. Cells were spun down and resuspended in Trizol
containing 0.1 mg/mL tRNA.
To isolate LSK HSPC, BM cells were stained with biotinylated
lineage antibodies (CD3, CD5, B220, CD11b, Gr-1, CD41,
Ter119) and SAV-APCCY7, Sca1-PE and Kit-APC. LSK cells
collected for in vitro culture were grown in X-Vivo supplemented
with 0.1% human serum albumin (CSL, Australia), rhuIL-6
(10 ng/mL), rhuIL-11 (10 ng/mL), rratKIT ligand (100 ng/mL)
and rhuFlt3 ligand (50 ng/mL). Recombinant huTIMP-3 (R&D,
USA) was added at a concentration of 200 ng/mL and the storage
buffer was used as control (25 mM Tris, 0.15 M NaCl pH 7.5).
Mice used for BrdU incorporation were given an intra-peritoneal
injection of 100 mg/kg BrdU and their water was supplemented
with 1 g/L BrdU three days prior to sacrifice. Sorted LSK cells
were cytospun onto glass slides, acetone fixed and BrdU stained as
per manufacturer’s protocol (BD Pharmingen, USA). BrdU slides
were counted blind.
For analysis of the donor/host chimerism, BM, spleen or blood
cells were pelleted at 370 g for 5 minutes at 4uC and resuspended
in Fc block. B cell chimerism was analyzed with CD45.1-PE,
CD11b-PECY7, B220-APCCY7 and CD19-Biotin-SAV-
PerCPCY5.5; myeloid and T cell chimerism with CD45.1-PE,
CD11b-PECY7, CD45.2-PerCPCY5.5, Gr-1-APCCY7 and CD3-
biotin with SAV-APC. LSK cells were stained with biotinylated
lineage antibodies (CD3, CD5, B220, CD11b, Gr-1, CD41,
Ter119) and SAV-PerCpCY5.5, CD150-PE, Sca1-PECY7, Kit-
APC and CD48-Pacific Blue.
Cell sorting was performed on the BD FACSAria Cell-Sorting
System (USA). FACS analysis data was collected on BD’s LSRII
System and analyzed using FlowJo (Tree Star, USA). All
antibodies were from BD Pharmingen except CD48-Pacific Blue,
CD41-Biotin and CD150-PE from BioLegend.
Isolation of Serum, Plasma and Platelets
For serum collection, whole blood was left at room temperature
for 1 hr and then ice for 30 min. Blood for plasma and platelet
lysis was collected in citrate dextrose and spun at 735 g for 20 min.
The supernatant was re-spun at 1,310 g for 30 min. The
supernatant (plasma) was removed and pelleted platelets were
lysed on ice for 35 min in 50 mM Tris pH 7.5 and 1%NP40
contain the inhibitors pepstatin A (1 mg/mL), leupeptin (2 mg/
mL), E64 (5 mg/mL), aprotinin (10,000 U/mL) and phenyl-
methylsulfonyl fluoride (0.2 mM) before centrifugation at
15,000 g. All supernatant were frozen at -70uC.
Reverse Zymography
Samples of equal protein concentration, as determined by
Micro BCA Protein Assay Kit (Pierce), were run in a 15%
polyacrylamide gel containing 2.25 mg gelatin (Ajax, Australia)
and 10 mg rhuPro-MMP-2 (R&D). The gel was washed in 2.5%
Table 1. RT-qPCR primers used for mouse and human TIMP-3
analysis.
muTIMP3 564f 59-ACACGGAAGCCTCTGAAAGTC-39
muTIMP3 691b 59-ACTTTGTGGAGAGGTGGGAC-39
huTIMP-3 255f 59-AGCTTCCGAGAGTCTCTGTG -39
huTIMP-3 371b 59-CACCTCTCCACGAAGTTGC-39
mu/huTIMP3 probe 639b 59-ACGCGCCCTGTCAGCAGGTA-39
muB2M 75f 59-CTGGTCTTTCTGGTGCTTGTC -39
muB2M 181b 59-GTATGTTCGGCTTCCCATTC-39
muB2M probe 94f 59-CACTGACCGGCCTGTATGCTATCCA-39
doi:10.1371/journal.pone.0013086.t001
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containing 50 mM Tris pH 7.5, 200 mM NaCl, 5 mM CaCl2
and 0.02% Brij-35. Activated MMP-2 degraded its substrate
gelatin except for areas where TIMPs were present. Areas of
MMP inhibition were visible following Coomassie Blue staining.
Positive control was either 25 ng of rhuTIMP-3 (R&D) or 20 ng of
rmuTIMP-3 (Abcam). Integrated intensity of TIMP-3 bands were
quantified using the 700 channel on Odyssey Infrared Imaging
System (Li-Cor Biosciences).
Immunohistofluorescence
Standard dewaxing and immunofluorescence protocol was
performed before following manufacturer’s instructions for
Tyramide Signal Amplification (TSA) Kit (Perkin-Elmer). Poly-
clonal rabbit anti-muTIMP3 primary antibody (Abcam) or
purified non-immune rabbit IgG control (Jackson ImmunoRe-
search Laboratories) were used at 10 mg/mL, followed by donkey
F(ab)2 anti-rabbit IgG conjugated to horse radish peroxidase
(Jackson ImmunoResearch Laboratories). Biotinyl Tyramide
working solution was incubated for 8 minutes before washing
and incubation with streptavidin-AlexaFluor488 (Invitrogen).
Samples were mounted in ProLongGold containing 0.25 mg/mL
DAPI and analyzed on Zeiss LSM 510 Meta confocal laser
scanning microscope with the oil 40x objective. DAPI fluorescence
was excited at 405 nm with a diode laser and detected through a
420–480-nm band-pass filter. AlexaFluor 488 was excited at
488 nm with an argon laser and emission was detected through a
505–530-nm band-pass filter. Images are average of 16 consec-
utive scans and were analyzed using LSM 510 software (Zeiss,
Germany).
Bone Histology
Undecalcified tibias and femurs were fixed overnight in 4%
paraformaldehyde, transferred into 70% ethanol and embedded in
methacrylate as previously described [79]. Undecalcified 5 mm
sections were stained with toluidine blue or von Kossa [79].
Vector Construction
The coding region of huTIMP-3 was amplified from a plasmid
kindly provided by Dr MC Rio (IGBNC, France) using DeepVent
(New England Biolabs, USA). The primers used were as follow:
huTIMP-3-279f 59-AGAATTCAGATCTGCAGCGGCAATG-
ACCCCTTGG-39 (containing additional EcoRI and BglII
restriction sites upstream of the huTIMP-3 kozak sequence and
start codon) and huTIMP-3-937b 59-CCCTGAGCGCCA-
GACCCTGCCTCGAGTC-39 (containing the huTIMP-3 stop
codon followed by an XhoI restriction site). DNA sequence
integrity was confirmed using Big Dye Terminator v3 (Applied
Biosystems, USA), huTIMP-3 cDNA was cloned into dephos-
phorylated MXIE [42] at the EcoRI restriction site. Ligation was
performed using T4 DNA Ligase (Promega, USA) as per
manufacturer’s instruction and plasmid was electroporated into
JM109 bacterial cells. Insert orientation was determined by
restriction digest with HindIII.
Retroviral Transduction
Empty MXIE or MXIE-huTIMP-3 plasmids linearised with
ScaI, and HindIII-lineared DsRed vector containing a neomycin
resistance cassette, were co-transfected into the ecotropic packag-
ing cell line GP+E-86 with Metafectene (Biontex, Germany). Cells
were incubated in Dulbecco’s Modified Eagle Medium supple-
mented with 10% FCS overnight. G418 (0.5 mg/mL) was added
to select stable transfectants. After 2 weeks of selection, transfected
GP+E-86 cells expressing GFP from MIXIE vectors were sorted
by FACS and seeded in a clonal fashion in 96-well plates. The
highest GFP expressing stable transfectant clones were irradiated
at 15Gy to stop replication capacity and used to transfect mouse
myeloid cell line FDC-P1, or mouse BM cells by a 3 day co-
culture. RNA and genomic DNA were collected for PCR using the
cloning primers listed above, cell lysate and supernatant were
collected for reverse zymography.
Transplantation of Retrovirally Transduced HSC
Donor B6.SJL-PtprcaPep3b/BoyJ mice were injected intravei-
nously 150 mg/kg 5-fluorouracil. Mononucleated BM cells were
collected from four days later and co-cultured for 3 days with
irradiated GP+E-86 packaging cells transfected with either empty
MXIE or MXIE-huTIMP-3 plasmids in a ratio of five BM cells to
one packaging cell in IMDM supplemented with 15% FCS, 4 mg/
mL polybrene (Sigma Chemicals), 100 ng/mL rratSCF, 50 ng/
mL rhuFlt3L, 10 ng/mL rhuIL-6 and 10 ng/mL rhuIL-11
(Preprotec). Post culture, 1610
6 transduced BM cells were washed
and retro-orbitally injected into C57BL/6 mice lethally irradiated
with two split doses of 5.5Gy each 24 hours prior to transplant.
Mice were bled via the tail vein at 8weeks post-transplant to assess
engraftment levels by flow cytometry (CD45.1 vs CD45.2 and
GFP positivity).
Statistics
Significance levels were calculated using the Mann-Whitney test
in GraphPad Prism v5.01. Survival statistics was calculated in the
same program using the Log-rank (Mantel-Cox) test.
Supporting Information
Figure S1 Lack of effect of huTIMP-3 overexpression in
hematopoietic cells on mouse weight and white blood cell counts
in blood, BM and spleen 14 weeks post-transplant. RT-qPCR for
huTIMP-3 expression (A) and endogenous muTIMP-3 expression
(B) in central BM cells and endosteal cells from mice transplanted
with HSC transduced with empty MXIE vector or MXIE-
huTIMP3 vector. Data are normalized to B2M mRNA and are
mean6SD of 5 mice per group. UND is for undetected. Body
weight (C), spleen weight (D), white cell counts in spleen (E), femur
(F) and blood (G). Data are mean6SD of 9 mice per group.
Found at: doi:10.1371/journal.pone.0013086.s001 (0.77 MB TIF)
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